© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
September 18, 2022
Ophthalmologists should instruct their patients to pay attention to their eye health for the long term.
September 06, 2022
A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.
August 24, 2022
Although predefined co-primary study endpoints were not met, AR-15512 demonstrated statistically significant improvements in DED signs, symptoms, and disease-related quality of life.
August 23, 2022
According to the company, topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieve persistent ocular discomfort in severe dry eye disease.
August 21, 2022
With a few key steps, surgeons can avert potential refractive surprises, and reduce postoperative dry eye for patients.
August 20, 2022
Reservoir restoration can re establish the normal anatomy and function of the conjunctiva.
August 20, 2022
By creating customized packages that incorporate the range of diagnostic and treatment options available, practices can simplify dry eye management and improve patients' outcomes.
August 17, 2022
Oyster Point Pharma Inc. today announced that the largest Medicare pharmacy benefit manager in the United States will add its varenicline solution nasal spray (Tyrvaya) for the treatment of dry eye on its Medicare Part D formularies, effective September 1.
August 16, 2022
An independent data monitoring committee recommends continuing study with a sample size target of up to 350 Patients. According to the company, no safety concerns have been identified and topline results are expected during the second quarter of 2023.
August 11, 2022
ThermaMEDx today announced a partnership with EyeCare Partners to expand EverTears distribution across the network of the national provider of clinically integrated eye care.